Operationalizing Use of Long-Acting Injectable ART

Shireesha Dhanireddy
University of Washington

Last Updated: 02 June 2021
Disclosures

No conflict of interest or relationships to disclose
Summary of Data from ATLAS and FLAIR Studies

• CAB/RPV IM q 4 weeks was non-inferior to oral options studied
• Injection site reactions not uncommon
• Satisfaction was high (97% and 99% preferred IM to PO)
• Low rates of virologic failure (3 in each study)
• When virologic failure occurred, NNRTI and INSTI resistance emerged (no cross resistance to DTG seen)
• 35 year old woman is interested in LA-ART. She is tired of taking pills daily.
Your patient if interested in CAB/RPV

• Eligibility Criteria
  - Patient interest
  - Understands monthly visits for 2 injections each time
  - Understands that there is a 4-week oral lead-in
  - Has been suppressed for at least 3 months (although 6 months was used in the studies)
Your patient if interested in CAB/RPV

- Ineligibility criteria
  - Resistance (okay to have a K103N only)
  - HBV positive (if not planning to take oral HBV active agent)
  - Clade A1 or L74I polymorphism
  - h/o poor adherence (until LATITUDE trial data available)
  - Pregnancy or planning to become pregnant
Your patient meets criteria

- Place referral to pharmacy for CAB/RPV (Cabenuva)
- Pharmacy and provider team will clinically review
- PC (program coordinator) will obtain insurance approval (PA)
- Once approved, pharmacy will schedule in person visit to review
  - Prescribes the oral lead in from Viiv
  - Schedules visit for loading injections and subsequent first maintenance injections (pharmacy and nursing visits)
Referral to Pharmacy

• Reason for referral

• Therapy/Medication(s) to Review (Select all as default – can choose individual as needed):
  - Oral Lead-in:
    • Cabotegravir 30mg – Take 1 tablet daily #30 tablets
    • Rilpivirine 25mg – Take 1 tablet daily #30 tablets
  - Initiation Injection: 600-mg/900-mg kit:
    • 600-mg single-dose vial of cabotegravir IM x 1 dose +
    • 900-mg single-dose vial of rilpivirine IM x 1 dose
  - Continuation Injections: 400-mg/600-mg kit:
    • 400-mg single-dose vial of cabotegravir IM x 1 dose monthly +
    • 600-mg single-dose vial of rilpivirine IM x 1 dose monthly

• Most recent HIV RNA undetectable and within the last 3 months

• HIV genotype documented

• HBV status

• Pregnancy status

From Ji Lee, PharmD
Your patient meets criteria

- Place referral to pharmacy for CAB/RPV (Cabenuva)
- Pharmacy and provider team will clinically review
- PC (program coordinator) will obtain insurance approval (PA)
- Once approved, pharmacy will schedule in person visit to review
  - Prescribes the oral lead in from Viiv
  - Schedules visit for loading injections and subsequent first maintenance injections (pharmacy and nursing visits)
Ensuring adherence with maintenance dosing

- RN champion to track patients

- What happens if patients missed doses
  - Bridge dosing for planned missed injections
  - If unplanned, has 7-day grace period to get f/u injection
  - If unplanned and more than 7 days after missed injections, then need oral bridge (which will need to be ordered)
  - Patients may need reloading
Considerations for Ineligibility

- Missed injections and requiring more than 2 additional loading doses in a 6-month period
- Pregnancy or desire to become pregnant
Status of LA-ART at Madison

- We have yet to start anyone
- Lots of provider interest, some patient interest
Acknowledgment

The Mountain West AIDS Education and Training (MWAETC) program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $2,990,665 with 0% financed with non-governmental sources.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.